Paper Details

  1. Home
  2. Paper Details

Assessment and management of bone health in women with early breast cancer receiving endocrine treatment in the DATA study.

Author: , ErdkampFrans L G, HonkoopAafke H, ImholzAlexander L T, KroepJudith R, LinnSabine C, PeerPetronella G M, SeynaeveCaroline M, SmorenburgCarolien H, SwinkelsAstrid C P, Tjan-HeijnenVivianne C G, de BoerMaaike, de GraafHiltje, de RoosWilfred K, van HellemondIrene E G, van den BerkmortelFranchette W P J, van der SangenMaurice J C

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Extended anastrozole therapy (6 years) was not associated with a higher incidence of osteoporosis compared to shorter therapy (3 years). Anastrozole use was associated with a modest decrease in bone mineral density, partially reversible after anastrozole cessation.
Paper Details　
Original Abstract of the Article :
The phase III DATA study investigates the efficacy of adjuvant anastrozole (6 vs. 3 year) in postmenopausal women with breast cancer previously treated with 2-3 years of tamoxifen. This planned side-study assessed patterns of care regarding detection and treatment of osteopenia/osteoporosis, and tre...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6767695/

データ提供：米国国立医学図書館（NLM）

Bone Health in Women with Early Breast Cancer Receiving Endocrine Treatment

Early breast cancer, a formidable foe, can be effectively treated with endocrine therapy. However, a potential side effect of this treatment is bone loss. This study investigated the impact of endocrine therapy on bone health in women with early breast cancer, shedding light on the potential risks and strategies for management.

Navigating the Desert of Bone Health

The researchers found that extended anastrozole therapy, a commonly used endocrine treatment, was not associated with a higher incidence of osteoporosis. However, they observed a modest decrease in bone mineral density during anastrozole treatment. This finding underscores the importance of monitoring bone health in patients receiving endocrine therapy, emphasizing the need for proactive interventions to prevent bone loss. It's like ensuring a camel caravan is well-equipped with supplies to navigate the arid desert landscape.

Protecting Bone Health During Treatment

The study highlights the importance of regular bone mineral density measurements and the potential use of bisphosphonates to protect bone health in patients receiving endocrine therapy. This proactive approach can help to mitigate the risk of osteoporosis and maintain bone strength. It's like providing a camel with a reliable source of water in the desert, ensuring its survival and resilience.

Dr.Camel's Conclusion

This research provides valuable insights into the impact of endocrine therapy on bone health in women with early breast cancer. It emphasizes the importance of monitoring bone health and implementing preventive measures to minimize the risk of osteoporosis. Just as a wise traveler navigates the desert, so too must we approach healthcare with a proactive and informed approach to ensure optimal outcomes.

Date :
  1. Date Completed 2020-01-13
  2. Date Revised 2020-01-13
Further Info :

Pubmed ID

30748011

DOI: Digital Object Identifier

PMC6767695

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.